EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma

Laura Zarzuela, Ignacio G López-Cepero, Kevin M Rattigan, Ana Reina-Bando, Jorge Martín-Montalvo, Jesús M Sierra-Párraga, Elena Sánchez-Escabias, Macarena Morillo-Huesca, Sara S Oltra, María Ceballos-Chávez, Vivian Capilla-González, Gema Moreno-Bueno und 5 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Laura Zarzuela und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Univ…. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Drug Resistance, Neoplasm, Receptor, Fibroblast Growth Factor, Type 1. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund, Instituto de Salud Carlos III, CIBERONC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapy resistance is a major limitation in therapeutic efficacy for glioblastoma (GBM) patients, positioning GBM among the deadliest tumor types. In this work, we have dissected resistance mechanisms in GBM, which resulted in the identification of FGFR1 pathway as a major controller of the signaling and metabolic rewiring associated to temozolomide (TMZ) resistance. Hence, in FGFR1-positive, p53 WT GBM cells, FGFR1 controls a p53-mediated cell cycle arrest to allow DNA repair in response to TMZ. FGFR1 also regulates a complete metabolic rewiring promoting lipid catabolism and preventing lipid peroxidation. Indeed, FGFR1 inhibition completely abolishes this signaling and metabolic reprograming, restoring sensitivity to TMZ. Our results also indicated a correlation of FGFR1 with poor prognosis in GBM patients, and validated the dual treatment with TMZ and FGFR1 inhibitors as an efficient strategy to induce tumor cell death in FGFR1-positive, p53 WT pre-clinical animal GBM models. These data position FGFR1 as a promising candidate for future clinical evaluation to limit therapy resistance to TMZ in FGFR1-positive GBM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaDrug Resistance, NeoplasmReceptor, Fibroblast Growth Factor, Type 1Brain NeoplasmsAntineoplastic Agents, AlkylatingHumansAnimalsCell Line, TumorMetabolic ReprogrammingSignal TransductionTumor Suppressor Protein p53Xenograft Model Antitumor AssaysLipid PeroxidationMice

Stichwörter der Autor:innen

FGFR1GBMLipidomicsMetabolic reprogramingTMZTherapy resistance

Substanzen

TemozolomideReceptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanAntineoplastic Agents, AlkylatingTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Universidad Pablo de Olavide, Fundación Progreso y Salud, Junta de Andaluc…
  • Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK.
  • Instituto de Investigaciones Biomedicas "Sols-Morreale" CSIC-UAM, C/Arturo Dupurier 4, Madrid, 28029, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; L…

Förderung

  • European Regional Development Fund
  • Instituto de Salud Carlos III
  • CIBERONC
  • Ministerio de Universidades
  • Ministerio de Ciencia, Innovación y Universidades
  • Junta de Andalucía
  • State Agency of Research
  • Federación Española de Enfermedades Raras

Zitieren

APA

Zarzuela, L., López-Cepero, I. G., Rattigan, K. M., Reina-Bando, A., Martín-Montalvo, J., Sierra-Párraga, J. M., Sánchez-Escabias, E., Morillo-Huesca, M., Oltra, S. S., Ceballos-Chávez, M., Capilla-González, V., Moreno-Bueno, G., Murdoch, P. D. S., Reyes, J. C., Helgason, G. V., Tomé, M., & Durán, R. V. (2026). FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218565

Vancouver

Zarzuela L, López-Cepero IG, Rattigan KM, Reina-Bando A, Martín-Montalvo J, Sierra-Párraga JM, et al. FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218565

BibTeX
@article{Zarzuela2026,
  author = {Zarzuela, Laura and López-Cepero, Ignacio G and Rattigan, Kevin M and Reina-Bando, Ana and Martín-Montalvo, Jorge and Sierra-Párraga, Jesús M and Sánchez-Escabias, Elena and Morillo-Huesca, Macarena and Oltra, Sara S and Ceballos-Chávez, María and Capilla-González, Vivian and Moreno-Bueno, Gema and Murdoch, Piedad Del Socorro and Reyes, José C and Helgason, G Vignir and Tomé, Mercedes and Durán, Raúl V},
  title = {FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218565}
}
Kostenlos starten →